SCYNEXIS inc (NASDAQ:SCYX) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.
SCYNEXIS inc (NASDAQ:SCYX) gained 4.69 Percent and closed its previous trading session at $2.01. The stock traded with the average Volume of 687.16 Million at the end of last session.
SCYNEXIS inc (NASDAQ:SCYX) has the Market Capitalization of 91.98 Million. The Stock has its 52-week High of $2.50 and 52-Week Low of $1.05 and it touched its 52-week high on 10/05/17 and 52-Week Low on 04/25/18
The company reported its last earnings Actual EPS of $-0.12/share. While, the analyst predicted that the company could provide an EPS of $-0.19/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.07/share which shows an Earnings Surprise of 36.8 Percent.
Sell side analysts plays vital role in buying and selling a stock where 5 analysts rated SCYNEXIS inc (NASDAQ:SCYX) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 14.87% where SMA50 and SMA200 are 24.32% and 13.14% respectively.
The company shows its Return on Assets (ROA) value of -45.5%. The Return on Equity (ROE) value stands at -82.6%.
SCYNEXIS inc (NASDAQ:SCYX) currently has a Weekly Volatility of 10.76% percent while its Monthly Volatility is at 8.07% percent. While talking about Performance of the Stock, SCYNEXIS inc currently has a Weekly performance of 16.86%, monthly performance percentage is 18.24 percent, Quarterly performance is 54.62 percent, 6 months performance shows a percent value of 2.03% and Yearly Performance is 8.65 percent.
SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina.